Allopurinol: Nursing Drug Guide, Hypersensitivity Rash & Hold Rules
Allopurinol lowers uric acid by blocking xanthine oxidase, but the bedside priority is hypersensitivity: Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS are reported—often after a seemingly mild rash. Labeling requires permanent discontinuation at the first rash. Pair slow renal titration, colchicine or NSAID flare prophylaxis on initiation, adequate hydration, and interaction checks (warfarin, azathioprine/mercaptopurine) with every dose.
Allopurinol can cause serious and sometimes fatal skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS)—reported in approximately 5 in 10,000 patients per labeling. Discontinue permanently at the first appearance of any rash or other hypersensitivity sign; do not rechallenge. Risk is higher with HLA-B*58:01, renal impairment plus thiazide diuretics, and drugs such as ampicillin, amoxicillin, or bendamustine. Concurrent gout flares are expected when urate mobilizes—use prophylactic colchicine or anti-inflammatory therapy, but never ignore new skin findings.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose: scan for new rash, mouth sores, fever, or peeling skin—hold and escalate immediately. On initiation, expect gout flares unless prophylaxis is running; verify eGFR-based dose, hydration (~2 L urine output/day when appropriate), and interaction review (warfarin/INR, azathioprine, pegloticase, capecitabine). Teach patients to stop allopurinol and seek care at the first rash—do not wait for the next clinic visit.
Most common brand names
Allopurinol is the generic name used on most inpatient and outpatient orders.
Common brands (United States): Zyloprim. An IV formulation (Aloprim) exists for hyperuricemia with malignancy—verify route and product if your unit stocks IV allopurinol; this guide focuses on oral tablets per the reviewed DailyMed oral label.
Why we give it — Indications
Allopurinol reduces serum and urinary uric acid by inhibiting xanthine oxidase. It is not recommended for asymptomatic hyperuricemia per labeling.
| Use | Detail |
|---|---|
| Gout | Adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, nephropathy) |
| Tumor lysis prevention | Adults and pediatric patients with leukemia, lymphoma, or solid tumors when cancer therapy raises serum and urinary uric acid—start 24–48 h before cytolytic therapy per labeling |
| Recurrent calcium oxalate stones | Adults with recurrent calculi and daily uric acid excretion >800 mg (men) or >750 mg (women) despite lifestyle changes |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Allopurinol is a structural analogue of hypoxanthine. It inhibits xanthine oxidase, blocking conversion of hypoxanthine → xanthine → uric acid. The active metabolite oxypurinol (oxipurinol) also inhibits xanthine oxidase and is renally eliminated—accumulation occurs when kidney function declines. Lower serum uric acid mobilizes tissue urate deposits, which is why acute gout flares can occur during initiation even when levels fall.
Dosing overview
Individualize dose to serum uric acid target and renal function. For gout, obtain baseline serum uric acid, CBC, chemistry panel, and liver function tests before starting per labeling.
Table 1 — Initial gout dose by eGFR (labeling)
| eGFR (mL/min) | Initial daily dose |
|---|---|
| >60 | No modification (100 mg daily standard start) |
| 30–60 | 50 mg daily |
| 15–30 | 50 mg every other day |
| 5–15 | 50 mg twice weekly |
| <5 | 50 mg once weekly |
On a small screen, swipe or scroll sideways to see the full table.
Missed dose: If a dose is missed, there is no need to double the next scheduled dose per labeling.
Before you give it — Safety check
Pretreatment checks
- Review allergy history to allopurinol; prior severe rash = do not administer
- Baseline serum uric acid, CBC, BMP/creatinine, eGFR, ALT/AST, alkaline phosphatase, bilirubin for gout starts
- Confirm flare prophylaxis ordered (colchicine or NSAID per prescriber) when initiating urate-lowering therapy
- Screen medication list: warfarin, azathioprine/mercaptopurine, thiazide, ampicillin/amoxicillin, pegloticase, capecitabine, cyclosporine
- Full skin assessment—document absence of rash; teach patient to report new lesions immediately
Contraindications
- Known hypersensitivity to allopurinol or any tablet ingredient
- Prior serious hypersensitivity reaction to allopurinol (do not rechallenge)
- Not specified in the reviewed prescribing information as an absolute contraindication: asymptomatic hyperuricemia alone (drug not recommended for this use)
Important interactions
| Drug / factor | Effect | Nursing action |
|---|---|---|
| Azathioprine / mercaptopurine | Allopurinol inhibits metabolism → higher exposure, myelosuppression | Expect ~⅓–¼ immunosuppressant dose with 300–600 mg allopurinol; monitor CBC; pharmacy coordination mandatory |
| Warfarin | May enhance anticoagulant effect | Assess INR frequently when allopurinol is added or dose changes |
| Thiazide + renal impairment | Increased hypersensitivity rash risk | Reduce allopurinol dose; stop at first rash; monitor creatinine |
| Ampicillin / amoxicillin / bendamustine | Increased severe rash risk | Discontinue allopurinol at first rash when used concomitantly |
| Pegloticase | Blunted uric acid rise → anaphylaxis risk | Do not start allopurinol during pegloticase; discontinue allopurinol before pegloticase per labeling |
| Capecitabine / fluorouracil | May reduce capecitabine efficacy; possible 5-FU interaction | Avoid concomitant capecitabine; avoid fluorouracil per labeling |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet (100 mg, 200 mg, 300 mg strengths per labeling).
- Generally better tolerated after meals per labeling
- Doses >300 mg/day should be given in divided doses
- Maintain hydration targeting ≥2 L urine output daily in adults when clinically appropriate to reduce xanthine calculi and urate precipitation
- Prefer alkaline or neutral urine when ordered to support urate solubility
Start low and titrate slowly—rapid escalation increases gout flares and serious adverse reactions per labeling. Continue allopurinol if a flare occurs; treat the flare concurrently unless hypersensitivity develops.
Expected therapeutic response
- Serum uric acid ≤6 mg/dL in gout management (prescriber target may vary)
- Shorter, less severe gout flares after several months of therapy
- Reduced tophi burden and joint destruction progression over long-term use
- During tumor lysis prophylaxis: uric acid within normal range with daily monitoring early in therapy
- Stable renal function and absence of new rash, cytopenias, or hepatotoxicity signs
Red flags — Stop and act
Any hypersensitivity cue requires immediate permanent discontinuation and escalation—do not administer the next scheduled dose.
- Any new rash, hives, blistering, mucosal lesions, or skin peeling (SJS/TEN/DRESS concern)
- Fever, facial swelling, eosinophilia, or systemic symptoms with rash
- Jaundice, dark urine, severe nausea, or rising ALT/AST with anorexia or pruritus
- Oliguria, flank pain, or rising creatinine suggesting acute kidney injury or xanthine calculi
- New severe joint pain with systemic illness—differentiate flare from hypersensitivity
- Bleeding, bruising, or infection signs with concurrent azathioprine/mercaptopurine (myelosuppression)
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Skin rash (maculopapular) | Most frequent reaction; may precede SJS/TEN/DRESS | Stop permanently; notify prescriber; document morphology and timing |
| Acute gout flare | Common on initiation (≥1%) | Continue allopurinol unless hypersensitivity; ensure prophylaxis; treat flare per order |
| GI: nausea, diarrhea | ≥1% | Give with food; differentiate from hepatotoxicity if jaundice or LFT rise |
| Elevated AST/ALT / alkaline phosphatase | ≥1%; reversible hepatotoxicity reported | Hold and notify if symptomatic or persistent elevation per prescriber |
| Myelosuppression | With cytotoxics or azathioprine/MP | Monitor CBC; infection precautions; pharmacy dose review |
| Renal failure / nephritis | Post-marketing | Monitor I&O and creatinine; maintain hydration; hold if AKI |
| CNS: drowsiness, dizziness | Reported | Fall precautions; advise caution with alcohol and other sedatives |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Not specified in the reviewed prescribing information for typical overdose signs. Management is supportive.
Labeling guidance
- No specific antidote for allopurinol tablets overdose
- Allopurinol and oxypurinol are dialyzable; usefulness of hemodialysis or peritoneal dialysis in overdose is unknown
- Contact poison control or medical toxicology services per facility protocol and local emergency guidance for significant ingestion
Look-alike / sound-alike and error prevention
- Allopurinol vs febuxostat—both lower uric acid; different hypersensitivity profile—verify drug name on MAR
- Allopurinol vs colchicine—colchicine treats flares; allopurinol lowers urate—common coprescribing; do not swap
- Allopurinol vs probenecid—uricosuric vs xanthine oxidase inhibitor—opposite mechanisms
- Dose confusion—100 mg vs 300 mg tablets; renal patients often start 50 mg—independent double-check
- Home bottle continuation—reconcile outpatient allopurinol at admission; rash on day 3 may be drug-related
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| First rash | Stop allopurinol permanently; photograph lesion if policy allows; notify prescriber and pharmacy same shift |
| Flare vs allergy | Localized hot swollen joint without rash may be gout flare—continue allopurinol + flare treatment per order |
| Renal titration | Use 50 mg increments every 2–4 weeks when eGFR <60—do not use 100 mg weekly renal pathway |
| Hydration | Encourage fluids unless restricted; document urine output when monitoring for stones or tumor lysis |
| Oncology patients | Start 24–48 h before chemotherapy; discontinue when tumor lysis risk abates per prescriber |
| Ask pharmacy when | Azathioprine/MP on board, warfarin INR unstable, eGFR <30, or HLA-B*58:01 screening questions |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| HLA-B*58:01 carriers | Higher hypersensitivity risk; allopurinol not recommended unless benefits clearly outweigh risks |
| Asian, African, Native Hawaiian/Pacific Islander ancestry | Higher HLA-B*58:01 prevalence—consider screening where locally available before start |
| Chronic kidney disease | Lower initial dose; monitor creatinine; decrease or withdraw if persistent kidney function decline |
| Thiazide diuretic users | Increased rash risk especially with renal impairment—reduce allopurinol dose |
| Leukemia / lymphoma on chemotherapy | Tumor lysis dosing; daily uric acid and kidney monitoring early; myelosuppression risk with cytotoxics |
| Pregnancy | Labeling: may cause fetal harm based on animal data; use only if benefit justifies risk; advise potential risk |
| Lactation | Labeling: do not breastfeed during therapy and for one week after last dose; allopurinol and oxypurinol present in milk |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Skin at every visit—including oral mucosa and genital areas
- Serum uric acid toward prescriber goal (often ≤6 mg/dL)
- Creatinine, BUN, eGFR, urine output—especially first months and with uric acid trends
- CBC if myelosuppressive co-therapy or cytopenia symptoms
- ALT, AST, alkaline phosphatase, bilirubin if GI symptoms or pruritus
- INR when combined with warfarin (assess per anticoagulation protocol)
Document
- Baseline and trend uric acid, renal function, LFTs, and eGFR-based dose adjustments
- Flare prophylaxis on MAR and patient education provided
- Rash assessments with date/time; permanent discontinuation orders if hypersensitivity
- Pharmacy consultation for azathioprine/mercaptopurine dose changes
Patient teaching
- Stop allopurinol immediately and seek medical care at the first sign of rash, mouth sores, blistering, or peeling skin
- Gout flares may occur when starting—continue allopurinol unless told otherwise; take prescribed flare medicine
- Drink adequate fluids unless fluid-restricted to help prevent kidney stones
- Take after meals if nausea occurs; do not double doses if one is missed
- Report yellowing skin or eyes, unusual bleeding, severe joint swelling with fever, or decreased urination
- Do not breastfeed during therapy and for one week after the last dose per labeling
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Any new rash, hives, mucosal lesion, or suspected hypersensitivity—hold permanently per labeling
- Known hypersensitivity to allopurinol
- Order lacks required renal dose reduction when eGFR is impaired
- Active pegloticase therapy—do not administer allopurinol
- Significant AKI, oliguria, or persistent creatinine rise without prescriber clearance
- Concurrent capecitabine order (avoid combination per labeling)
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Allopurinol is long-term therapy—errors show up as a “minor rash” that progresses to catastrophic hypersensitivity, or as an AKI from wrong renal titration during a gout admission. Build rash surveillance into every administration.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, time—and right eGFR-based dose
- Skin check: no new lesions since last dose
- Verify flare prophylaxis active when within first months of therapy
- Interaction scan: warfarin, azathioprine/MP, thiazide, antibiotics, pegloticase
2. High-alert and safety badge
Severe hypersensitivity risk — permanent stop at first rashAlthough not on all institutional high-alert lists, labeling emphasizes fatal dermatologic reactions. Treat any new rash as a medication safety stop until prescriber and allergy review—do not readminister.
3. Clinical workflow: hold and question rules
- If the patient reports itching or a spot on the trunk, hold the dose and escalate before the next pass
- If eGFR drops and dose still uses weekly 100 mg titration, call pharmacy for Table 1 adjustment
- If INR supratherapeutic after allopurinol start, notify prescriber and reinforce bleeding precautions
4. Critical teach-back questions
- “What will you do if you notice a new rash while taking allopurinol?” (Patient should say stop the medicine immediately and seek medical care today—not wait.)
- “Can you stop allopurinol when your toe hurts from a gout flare?” (Patient should say continue allopurinol unless the clinician told them otherwise and use flare treatment as prescribed.)
5. Care coordination
Pharmacist: Renal titration, azathioprine/MP dose reduction, warfarin INR plan, HLA screening logistics, tumor lysis dosing
Prescriber / rheumatology / nephrology: Refractory gout, recurrent flares despite prophylaxis, renal decline, or any suspected hypersensitivity
🧠 Quick mental checklist
- Any new rash, mouth ulcer, blister, or fever since the last dose?
- Is the dose appropriate for today’s eGFR—not the admission dose from last year?
- Is colchicine or NSAID prophylaxis on the MAR for a new start?
- Are warfarin, azathioprine, or thiazides present—and monitored?
- Is the patient drinking fluids and making adequate urine unless restricted?
Allopurinol NCLEX practice questions
Practice NCLEX-style clinical judgment practice for allopurinol hypersensitivity and gout safety using a tabbed outpatient case (MAR, labs, history, nursing notes), then priority action, cue recognition (SATA), uric acid trend interpretation, documentation cloze, ordered response, and matrix urgency—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Allopurinol 100 mg PO daily — given 0800 today
- Colchicine 0.6 mg PO twice daily prophylaxis — AM dose given
- Hydrochlorothiazide 25 mg PO daily — given 0800
- Warfarin 5 mg PO daily — held this AM pending INR
- Acetaminophen 650 mg PO PRN — not given
- Baseline (day 0): uric acid 9.8 mg/dL; creatinine 1.3 mg/dL; eGFR 52 mL/min/1.73 m²
- Day 7: uric acid 7.2 mg/dL; creatinine 1.4 mg/dL
- Today (day 14): uric acid 6.1 mg/dL; creatinine 1.5 mg/dL; eGFR 48 mL/min/1.73 m²; INR 3.6 (goal 2–3)
- ALT 32 U/L, AST 28 U/L — within reference range
- 58-year-old man admitted for gout flare management; allopurinol started on admission
- Hypertension, CKD stage 3, atrial fibrillation on warfarin
- No known drug allergies documented at admission
- Social: drinks 1–2 beers most evenings
- Reports new scattered pruritic red spots on trunk since morning; denies mucosal pain
- Right first MTP swollen, warm, pain 6/10 — improving vs admission
- Temp 37.1 °C; BP 128/76; denies shortness of breath
- Nurse preparing to administer 1400 colchicine and review evening allopurinol order
Answer key & rationale
Frequently asked questions
Why must nurses stop allopurinol at the first sign of rash?
Labeling reports serious and sometimes fatal dermatologic reactions including TEN, SJS, and DRESS. Discontinue permanently at the first appearance of skin rash or other hypersensitivity signs.
Should allopurinol be held during an acute gout flare?
Allopurinol need not be discontinued when a flare occurs during therapy; manage the flare with colchicine or anti-inflammatory therapy. Continue prophylaxis until uric acid is controlled and flares subside for several months.
How is allopurinol dosed when eGFR is reduced?
Initial gout dose is 50 mg daily when eGFR is 30–60 mL/min, with 50 mg increments every 2–4 weeks—not 100 mg weekly. See Table 1 in prescribing information for lower eGFR intervals.
What interaction requires azathioprine dose reduction?
Allopurinol inhibits xanthine oxidase metabolism of azathioprine and mercaptopurine. With 300–600 mg allopurinol daily, reduce immunosuppressant dose to about one third to one fourth usual and monitor for myelosuppression.
Is there an antidote for allopurinol overdose?
No specific antidote is listed. Allopurinol and oxypurinol are dialyzable, but usefulness of dialysis in overdose is unknown. Use supportive care and contact poison control per facility protocol.
Can patients breastfeed while taking allopurinol?
Labeling advises not to breastfeed during treatment and for one week after the last dose because of potential serious adverse reactions in the breastfed child.
References
- U.S. National Library of Medicine. Allopurinol tablet — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4a00a35a-cc85-0088-e063-6394a90a0744
- U.S. Food and Drug Administration. Allopurinol tablets — Prescribing information (label PDF).https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/018832s056s058s061,018877s063s065s068lbl.pdf
- U.S. National Library of Medicine. Allopurinol — MedlinePlus drug information.https://medlineplus.gov/druginfo/meds/a682673.html
- U.S. Food and Drug Administration. MedWatch: FDA Safety Information and Adverse Event Reporting Program.https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.